PERSPECTIVES OF URSODEOXYCHOLIC ACID APPLICATION IN CLINICAL PRACTICE

DOI: https://doi.org/10.29296/25877305-2024-07-09
Issue: 
7
Year: 
2024

A. Morozov, Candidate of Medical Sciences; A. Kadykov, Candidate of Medical Sciences; Professor N. Sergeev, MD; V. Bogochanov; D. Dmitrieva, E. Nilova
Tver State Medical University, Ministry of Health of Russia

The possibilities of ursodeoxycholic acid (UDCA) application in clinical practice are evaluated. Statistical analysis of data from modern Russian and foreign literature sources, as well as recent scientific works in the field of pharmacology of UDCA was carried out. UDCA has a significant potential, as it can affect both the body as a whole and its individual organs, systems and processes. This effect is realized either by immunomodulating properties of the acid or directly on the cells themselves through bile acid receptors (bile acids together with UDCA are able to perform the role of signaling molecules). It should be noted that in many studies antagonism of UDCA and other bile acids was observed.
Keywords: 
ursodeoxycholic acid
tauroursodeoxycholic acid
bile acids
pharmacodynamics

References: 
  1. Beuers U. Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol. 2006; 3 (6): 318–28. DOI: 10.1038/ncpgasthep0521
  2. Lazaridis K.N., Gores G.J., Lindor K.D. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol. 2001; 35 (1): 134–46. DOI: 10.1016/s0168-8278(01)00092-7
  3. Буеверов А.О. Возможности клинического применения урсодезоксихолевой кислоты. Consilium Medicum. 2005; 7 (6): 460–3 [Bueverov A.O. Vozmozhnosti klinicheskogo primeneniya ursodezoksikholevoy kisloty. Consilium Medicum. 2005; 7 (6): 460–3 (in Russ.)].
  4. Feng Y., Siu K., Wang N. et al. Bear bile: dilemma of traditional medicinal use and animal protection. J Ethnobiol Ethnomed. 2009; 5: 1–9. DOI: 10.1186/1746-4269-5-2
  5. Paumgartner G., Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002; 36 (3): 525–31. DOI: 10.1053/jhep.2002.36088
  6. Морозов А. М., Сороковикова Т. В., Жуков С. В. и др. Актуальные маркеры воспаления в клинической практике. Современные проблемы науки и образования. 2022; 3: 142 [Morozov A.M., Sorokovikova T.V., Zhukov S.V. et al. Current markers of inflammation in clinical practice. Modern problems of science and education. 2022; 3: 142 (in Russ.)]. DOI 10.17513/spno.31653
  7. Yoshikawa M., Tsujii T., Matsumura K. et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology. 1992; 16 (2): 358–64. DOI: 10.1002/hep.1840160213
  8. Ward J.B.J., Lajczak N.K., Kelly O.B. et al. Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon. Am J Physiol Gastrointest Liver Physiol. 2017; 312 (6): G550-G558. DOI: 10.1152/ajpgi.00256.2016
  9. Lajczak N. K., Saint-Criq V., O'Dwyer A.M. et al. Bile acids deoxycholic acid and ursodeoxycholic acid differentially regulate human β-defensin-1 and -2 secretion by colonic epithelial cells. FASEB J. 2017; 31 (9): 3848–57. DOI: 10.1096/fj.201601365R
  10. Mroz M.S., Lajczak N.K., Goggins B.J. et al. The bile acids, deoxycholic acid and ursodeoxycholic acid, regulate colonic epithelial wound healing. Am J Physiol Gastrointest Liver Physiol. 2018; 314 (3): G378-G387. DOI: 10.1152/ajpgi.00435.2016
  11. Морозов А.М., Сергеев А.Н., Сунгурова А.В. и др. Компьютерное моделирование раневого процесса (обзор литературы). Вестник медицинского института «РЕАВИЗ»: Реабилитация, Врач и Здоровье. 2023; 13 (1): 144–52 [Morozov A.M., Sergeev A.N., Sungurova A.V. et al. Computer simulation of the wound process (review of literature). Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH). 2023; 13 (1): 144–52 (in Russ.)]. DOI: 10.20340/vmi-rvz.2023.1.ICTM.1
  12. Joyce S.A., O'Malley D. Bile acids, bioactive signalling molecules in interoceptive gut-to-brain communication. J Physiol. 2022; 600 (11): 2565–78. DOI: 10.1113/JP281727
  13. Niu F., Li H., Xu X. et al. Ursodeoxycholic acid protects against lung injury induced by fat embolism syndrome. J Cell Mol Med. 2020; 24 (24): 14626–32. DOI: 10.1111/jcmm.15985
  14. Işik S., Karaman M., Çilaker Micili S. et al. Beneficial effects of ursodeoxycholic acid via inhibition of airway remodelling, apoptosis of airway epithelial cells, and Th2 immune response in murine model of chronic asthma. Allergol Immunopathol (Madr). 2017; 45 (4): 339–49. DOI: 10.1016/j.aller.2016.12.003
  15. Willart M.A.M., van Nimwegen M., Grefhorst A. et al. Ursodeoxycholic acid suppresses eosinophilic airway inflammation by inhibiting the function of dendritic cells through the nuclear farnesoid X receptor. Allergy. 2012; 67 (12): 1501–10. DOI: 10.1111/all.12019
  16. von Haehling S., Schefold J.C., Jankowska E.A. et al. Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. J Am Coll Cardiol. 2012; 59 (6): 585–92. DOI: 10.1016/j.jacc.2011.10.880
  17. Hanafi N.I., Mohamed A.S., Kadir S.H.S.A. et al. Overview of bile acids signaling and perspective on the signal of ursodeoxycholic acid, the most hydrophilic bile acid, in the heart. Biomolecules. 2018; 8 (4): 159. DOI: 10.3390/biom8040159
  18. Zhang R., Ma W.-Q., Fu M.-J. et al. Overview of bile acid signaling in the cardiovascular system. World J Clin Cases. 2021; 9 (2): 308. DOI: 10.12998/wjcc.v9.i2.308
  19. Ambros-Rudolph C.M., Glatz M., Trauner M. et al. The importance of serum bile acid level analysis and treatment with ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a case series from central Europe. Arch Dermatol. 2007; 143 (6): 757–62. DOI: 10.1001/archderm.143.6.757
  20. Akare S., Jean-Louis S., Chen W. et al. Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence. Int J Cancer. 2006; 119 (12): 2958–69. DOI: 10.1002/ijc.22231
  21. Zhang Y., Jiang R., Zheng X. et al. Ursodeoxycholic acid accelerates bile acid enterohepatic circulation. Br J Pharmacol. 2019; 176 (16): 2848–63. DOI: 10.1111/bph.14705
  22. Hofmann A.F. Medical dissolution of gallstones by oral bile acid therapy. Am J Surg. 1989; 158 (3): 198–204. DOI: 10.1016/0002-9610(89)90252-3
  23. Jüngst C., Kullak-Ublick G.A., Jüngst D. Microlithiasis and sludge. Best Pract Res Clin Gastroenterol. 2006; 20 (6): 1053–62. DOI: 10.1016/j.bpg.2006.03.007
  24. Poupon R.E., Balkau B., Eschwège E. et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med. 1991; 324 (22): 1548–54. DOI: 10.1056/NEJM199105303242204
  25. Shi J., Wu C., Lin Y. et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006; 101 (7): 1529–38. DOI: 10.1111/j.1572-0241.2006.00634.x
  26. Bowlus C.L., Kenney J.T., Rice G. et al. Primary biliary cholangitis: medical and specialty pharmacy management update. J Manag Care Spec Pharm. 2016; 22 (10): S3-S15. DOI: 10.18553/jmcp.2016.22.10-a-s.s3
  27. Poropat G., Giljaca V., Stimac D. et al. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2011; 2011 (1): CD003626. DOI: 10.1002/14651858.CD003626.pub2
  28. Lindor K.D., Kowdley K.V., Luketic V.A.C. et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology. 2009; 50 (3): 808–14. DOI: 10.1002/hep.23082
  29. McCabe M.E., Dilly C K. New causes for the old problem of bile reflux gastritis. Clin Gastroenterol Hepatol. 2018; 16 (9): 1389–92. DOI: 10.1016/j.cgh.2018.02.034
  30. Shi X., Chen Z., Yang Y. et al. Bile reflux gastritis: insights into pathogenesis, relevant factors, carcinomatous risk, diagnosis, and management. Gastroenterol Res Pract. 2022; 2022: 2642551. DOI: 10.1155/2022/2642551
  31. Xiang Z., Chen Y.-P., Ma K.-F. et al. The role of ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review. BMC Gastroenterol. 2013; 13: 1–8. DOI: 10.1186/1471-230X-13-140
  32. Маевская М.В., Надинская М.Ю., Луньков В.Д. и др. Влияние урсодезоксихолевой кислоты на воспаление, стеатоз и фиброз печени и факторы атерогенеза у больных неалкогольной жировой болезнью печени: результаты исследования УСПЕХ. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019; 29 (6): 22–9 [Mayevskaya M.V., Nadinskaia M.Yu., Lunkov V.D., et al. An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019; 29 (6): 22–9 (in Russ.)]. DOI: 10.22416/1382-4376-2019-29-6-22-29
  33. Волынец Г.В., Хавкин А.И. Урсодезоксихолевая кислота и болезни печени. Лечащий врач. 2020; 6: 62–8 [Volynets G.V., Khavkin A.I. Ursodeoxycholic acid and hepatic diseases. Lechaschi Vrach. 2020; 6: 62–8 (in Russ.)]. DOI: 10.26295/OS.2020.75.99.012
  34. Cheng K., Ashby D., Smyth R.L. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev. 2017; 9 (9): CD000222. DOI: 10.1002/14651858.CD000222.pub4
  35. Saad R.A., Mahmoud Y.I. Ursodeoxycholic acid alleviates cholestasis-induced histophysiological alterations in the male reproductive system of bile duct-ligated rats. Reproductive Toxicology. 2014; 50: 87–97. DOI: 10.1016/j.reprotox.2014.10.011
  36. Mahmoud Y.I. Testicular immunohistochemical and Ultrastructural changes associated with chronic cholestasis in rats: Effect of ursodeoxycholic acid. Life Sci. 2015; 136: 52–9. DOI: 10.1016/j.lfs.2015.05.027
  37. Kwon Y.I., Yeon J.-D., Oh S.-M. et al. Protective effects of ursodeoxycholic acid against 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin-induced testicular damage in mice. Toxicol Appl Pharmacol. 2004; 194 (3): 239–47. DOI: 10.1016/j.taap.2003.09.024
  38. Akdemir A., Sahin C., Erbas O. et al. Is ursodeoxycholic acid crucial for ischemia/reperfusion-induced ovarian injury in rat ovary? Arch Gynecol Obstet. 2015; 292: 445–50. DOI: 10.1007/s00404-015-3646-9
  39. Lofthouse E.M., Torrens C., Manousopoulou A. et al. Ursodeoxycholic acid inhibits uptake and vasoconstrictor effects of taurocholate in human placenta. FASEB J. 2019; 33 (7): 8211–20. DOI: 10.1096/fj.201900015RR
  40. Zangerolamo L., Vettorazzi J.F., Rosa L.R.O. et al. The bile acid TUDCA and neurodegenerative disorders: An overview. Life Sci. 2021; 272: 119252. DOI: 10.1016/j.lfs.2021.119252
  41. Гайнетдинова А.Н., Залялютдинова Л.Н., Гудз Д.О. и др. Влияние урсодезоксихолевой кислоты на психоэмоциональное состояние пациентов с патологией печени. Современные проблемы науки и образования. 2019; 3: 129–9 [Gaynetdinova A.N., Zalyalyutdinova L.N., Gudz D.O. et al. Influence of ursodezochic acid on the psycho-emotional condition of patients with liver pathology. Modern problems of science and education. 2019; 3: 129–9 (in Russ.)].
  42. Lu X.U., Yang R.-R., Zhang J.-L. et al. Tauroursodeoxycholic acid produces antidepressant-like effects in a chronic unpredictable stress model of depression via attenuation of neuroinflammation, oxido-nitrosative stress, and endoplasmic reticulum stress. Fundam Clin Pharmacol. 2018; 32 (4): 363–77. DOI: 10.1111/fcp.12367
  43. Cheng L., Huang C., Chen Z. Tauroursodeoxycholic acid ameliorates lipopolysaccharide-induced depression like behavior in mice via the inhibition of neuroinflammation and oxido-nitrosative stress. Pharmacology. 2019; 103 (1-2): 93–100. DOI: 10.1159/000494139
  44. Беляк М.А., Буканова К.В. и др. Свидетельство о государственной регистрации базы данных № 2022620490 Российская Федерация. База данных учебно-методических материалов по дисциплине «Семиотика двигательных нарушений: центральный и периферический паралич»: №2022620297, заявл. 22.02.2022: опубл. 14.03.2022 [Belyak M.A., Bukanova K.V. et al. Svidetel'stvo o gosudarstvennoi registratsii bazy dannykh № 2022620490 Rossiiskaya Federatsiya. Baza dannykh uchebno-metodicheskikh materialov po distsipline «Semiotika dvigatel'nykh narushenii: tsentral'nyi i perifericheskii paralich»: №2022620297, zayavl. 22.02.2022: opubl. 14.03.2022 (in Russ.)].
  45. Daruich A., Jaworski T., Henry H. et al. Oral ursodeoxycholic acid crosses the blood retinal barrier in patients with retinal detachment and protects against retinal degeneration in an ex vivo model. Neurotherapeutics. 2021; 18 (2): 1325–38. DOI: 10.1007/s13311-021-01009-6
  46. Chung J., An S.H., Kang S.W. et al. Ursodeoxycholic acid (UDCA) exerts anti-atherogenic effects by inhibiting RAGE signaling in diabetic atherosclerosis. PLoS One. 2016; 11 (1): e0147839. DOI: 10.1371/journal.pone.0147839
  47. Oh A.R., Bae J.-S., Lee J. et al. Ursodeoxycholic acid decreases age-related adiposity and inflammation in mice. BMB Rep. 2016; 49 (2): 105. DOI: 10.5483/BMBRep.2016.49.2.173
  48. Goossens J.F., Bailly C. Ursodeoxycholic acid and cancer: From chemoprevention to chemotherapy. Pharmacol Ther. 2019; 203: 107396. DOI: 10.1016/j.pharmthera.2019.107396